Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status
Roberto Mina(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Stefania Bellucci(Johnson & Johnson (United States)), Silvia Mangiacavalli(Policlinico San Matteo Fondazione), Bernardo Rossini(Istituto Tumori Bari), Simona Pellizzaro(Johnson & Johnson (United States)), Fabrizio Iannello(Johnson & Johnson (United States)), Gianni Ghetti(Adresseavisen (Norway))
Cited by 5
Related Papers
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210
Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
|Transplantation and Cellular Therapy|2011|74
Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
|Clinical Cancer Research|2013|68
Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure
|Journal of Renal Nutrition|2004|61
Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure
|Journal of Renal Nutrition|2004|59